Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-901 in Advanced Solid Tumors
NCT05382936Phase 1Terminated
- Sponsor
- Stemline Therapeutics
- Start
- Mar 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SL-901 in solid tumor (advanced stage) (2 arms), sponsored by Stemline Therapeutics. Primary endpoints: Maximum Tolerated Dose, Appropriate Dosing Regimen and 2 more. Started Mar 2021; status: terminated.
02
Drugs
SL-901
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05382936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382936.